Adaptin Bio, Inc.
corporate_fare Company Profile
Adaptin Bio, Inc. (OTC:APTN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 6 items for APTN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 8/10. Across its 6 most recent items scored 7 or higher, the top rating is 9/10, with 5 rated 8 or above. Recent SEC coverage for APTN spans 10-Q, S-1, 424B3.
Recent high-impact activity:
- Adaptin Bio Q3: Cash Falls to $430K, Going Concern Doubt, Pay Deferred
- Adaptin Bio Files S-1 for Resale of 420K Shares Amid Going Concern Doubt and Material Weaknesses
- Adaptin Bio Opens Enrollment in Phase 1 Trial for Brain Tumor Therapy APTN-101
- Adaptin Bio Flags Going Concern, Material Weaknesses in Q2 10-Q
- Selling Stockholders Offer 4.1M Shares & Warrants; Company Receives No Proceeds Amid Going Concern Warning
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for APTN, detected from its recent SEC filings · based on capital-structure filings through 2026-08-28.
S-1 Registration for Resale · Going Concern Doubt Reiterated
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →